NCT01290354View on ClinicalTrials.gov

Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 12, 2011

Primary Completion Date

March 18, 2013

Study Completion Date

March 18, 2013

Conditions
Cancer
Interventions
DRUG

Lapatinib

Unlabelled, administered orally

DRUG

[11C] lapatinib

Radiolabelled, administered intravenously

Trial Locations (3)

EC1A 7BE

GSK Investigational Site, London

W12 0NN

GSK Investigational Site, London

W6 8RF

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01290354 - Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer | Biotech Hunter | Biotech Hunter